Skip to content

Tribune Therapeutics announces new CMC collaboration

Oslo, August 30, 2023

Tribune Therapeutics has announced a new CMC collaboration with industry leader Bayer’s BioPartnering Solution. The partnership accelerates the company’s continued pathway to treat fibrosis regardless the cause. The drug development expertise from Tribune Therapeutics together with Bayer’s experience in biologic manufacturing is ideal to further drive innovation.

Tribune Therapeutics is a pre-clinical stage biopharmaceutical company co-founded by HealthCap. Tribune is developing a fusion protein to treat patients with fibrotic disease. The fusion protein targets the CCN protein family, which is a group of signaling proteins central to the development of fibrosis.